PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 153 filers reported holding PROGENICS PHARMACEUTICALS IN in Q3 2018. The put-call ratio across all filers is 1.25 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $99,000 | +17.9% | 21,290 | +5.8% | 0.00% | 0.0% |
| Q4 2018 | $84,000 | -30.6% | 20,115 | +4.1% | 0.00% | -20.0% |
| Q3 2018 | $121,000 | -12.3% | 19,327 | +12.5% | 0.01% | -28.6% |
| Q2 2018 | $138,000 | +23.2% | 17,186 | +14.4% | 0.01% | +133.3% |
| Q1 2018 | $112,000 | +30.2% | 15,019 | +4.0% | 0.00% | +50.0% |
| Q4 2017 | $86,000 | -23.9% | 14,443 | -5.6% | 0.00% | 0.0% |
| Q3 2017 | $113,000 | +9.7% | 15,306 | +0.8% | 0.00% | 0.0% |
| Q2 2017 | $103,000 | – | 15,184 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 17,902,338 | $135,342,000 | 5.88% |
| TIGER MANAGEMENT L.L.C. | 1,288,454 | $9,741,000 | 1.91% |
| Phocas Financial Corp. | 1,047,181 | $7,917,000 | 0.69% |
| TUDOR INVESTMENT CORP ET AL | 2,370,503 | $17,921,000 | 0.62% |
| EAM Investors, LLC | 553,309 | $4,183,000 | 0.58% |
| Baker Brothers Advisors | 4,449,797 | $33,640,000 | 0.34% |
| TFS CAPITAL LLC | 463,740 | $3,506,000 | 0.33% |
| FEDERATED HERMES, INC. | 13,508,290 | $102,123,000 | 0.32% |
| Rotella Capital Management, Inc. | 36,473 | $276,000 | 0.24% |
| OXFORD ASSET MANAGEMENT LLP | 1,103,848 | $8,351,000 | 0.18% |